Pharma Mar Competitors

Nissan Chemical (OTCMKTS:NNCHY) and Pharma Mar (OTCMKTS:PHMMF) are both mid-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Nissan Chemical and Pharma Mar, as provided by MarketBeat.

Risk & Volatility

Nissan Chemical has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500.

Profitability

This table compares Nissan Chemical and Pharma Mar's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Nissan Chemical and Pharma Mar's revenue, earnings per share (EPS) and valuation.

Nissan Chemical has higher revenue and earnings than Pharma Mar. Pharma Mar is trading at a lower price-to-earnings ratio than Nissan Chemical, indicating that it is currently the more affordable of the two stocks.

Summary

Nissan Chemical beats Pharma Mar on 10 of the 11 factors compared between the two stocks.

Pharma Mar (OTCMKTS:PHMMF) and Auto Trader Group (OTCMKTS:ATDRY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharma Mar and Auto Trader Group, as provided by MarketBeat.com.

Risk and Volatility

Pharma Mar has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Auto Trader Group has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Insider and Institutional Ownership

0.1% of Auto Trader Group shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Pharma Mar and Auto Trader Group's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Pharma Mar and Auto Trader Group's revenue, earnings per share (EPS) and valuation.

Auto Trader Group has higher revenue and earnings than Pharma Mar.

Summary

Auto Trader Group beats Pharma Mar on 6 of the 7 factors compared between the two stocks.

Pharma Mar (OTCMKTS:PHMMF) and ANA (OTCMKTS:ALNPY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharma Mar and ANA, as provided by MarketBeat.com.

Risk and Volatility

Pharma Mar has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, ANA has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Profitability

This table compares Pharma Mar and ANA's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Pharma Mar and ANA's revenue, earnings per share (EPS) and valuation.

ANA has higher revenue and earnings than Pharma Mar.

Summary

ANA beats Pharma Mar on 6 of the 10 factors compared between the two stocks.

Pharma Mar (OTCMKTS:PHMMF) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Risk and Volatility

Pharma Mar has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharma Mar and Hikma Pharmaceuticals, as provided by MarketBeat.com.

Earnings and Valuation

This table compares Pharma Mar and Hikma Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Hikma Pharmaceuticals has higher revenue and earnings than Pharma Mar. Pharma Mar is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pharma Mar and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Hikma Pharmaceuticals beats Pharma Mar on 7 of the 8 factors compared between the two stocks.

Atos (OTCMKTS:AEXAY) and Pharma Mar (OTCMKTS:PHMMF) are both mid-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

0.1% of Atos shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Atos and Pharma Mar, as reported by MarketBeat.com.

Earnings and Valuation

This table compares Atos and Pharma Mar's top-line revenue, earnings per share and valuation.

Atos has higher revenue and earnings than Pharma Mar.

Volatility & Risk

Atos has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Profitability

This table compares Atos and Pharma Mar's net margins, return on equity and return on assets.

Summary

Atos beats Pharma Mar on 6 of the 7 factors compared between the two stocks.

The Berkeley Group (OTCMKTS:BKGFY) and Pharma Mar (OTCMKTS:PHMMF) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Risk & Volatility

The Berkeley Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Earnings and Valuation

This table compares The Berkeley Group and Pharma Mar's top-line revenue, earnings per share and valuation.

The Berkeley Group has higher revenue and earnings than Pharma Mar. Pharma Mar is trading at a lower price-to-earnings ratio than The Berkeley Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for The Berkeley Group and Pharma Mar, as reported by MarketBeat.com.

Profitability

This table compares The Berkeley Group and Pharma Mar's net margins, return on equity and return on assets.

Summary

The Berkeley Group beats Pharma Mar on 6 of the 7 factors compared between the two stocks.